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ABSTRACT
Background and aims Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave
improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in
clinical practice for an effectiveness difference between bupropion and nicotine replacement therapy (NRT), whether
the combination improves effectiveness and whether either treatment might be more beneficial for certain subgroups
of smokers. Design Open-label randomized controlled trial with 6-month follow-up. Setting Four UK National
Health Service (NHS) smoking cessation clinics. Participants Smokers (n = 1071) received seven weekly behavioural
support sessions and were randomized to an NRT product of their choice (n = 418), bupropion (n = 409) or NRT plus
bupropion (n = 244). Measures The primary outcome was self-reported cessation over 6 months, with biochemical
verification at 1 and 6months. Alsomeasuredwere baseline demographics, health history, smoking characteristics and
unwanted events during treatment. Findings Abstinence rates for bupropion (27.9%) and NRT (24.2%) were not
significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%)
was similar to that for either treatment alone. There was some evidence that the relative effectiveness of bupropion and
NRT differed according to depression (χ2 = 2.86, P = 0.091), with bupropion appearing more beneficial than NRT in
those with a history of depression (29.8 versus 18.5%). Several unwanted symptoms were more common with
bupropion. Conclusion There is no difference in smoking cessation effectiveness among bupropion, nicotine replace-
ment therapy and their combination when used with behavioural support in clinical practice. There is some evidence
that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression.
Keywords Bupropion, combination treatment, depression, NHS, NRT, randomized trial, smoking cessation,
varenicline.
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INTRODUCTION
The antidepressant bupropion hydrochloride SR (Zyban;
GlaxoSmithKline, London, UK)was introduced as the first
non-nicotine medicine for smoking cessation following
a manufacturer-sponsored Phase III trial [1]. The main
result showed bupropion to be substantially more
beneficial than a nicotine patch, the most widely used
type of nicotine replacement therapy (NRT) [odds ratio
(OR) = 2.07, 95% confidence interval (CI) = 1.22–3.53].
In combination, bupropion and the patch were superior
to the patch alone, although not compared with bupro-
pion alone.
Despite the importance of this primary result, only two
small trials have since compared bupropion with NRT,
both failing to showadifference [2,3].Whendata fromthe
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three trials are summarized, the result is equivocal
because of a suggestion of heterogeneity and uncertainty
about the most appropriate pooling model [4]. Bupropion
is more effective using fixed-effect modelling (OR = 1.54,
95%CI = 1.01–2.37), butnotwitha random-effectmodel
(OR = 1.34, 95% CI = 0.71–2.56). There has been more
interest in combination treatment, with five subsequent
small trials all failing to find a benefit for bupropion plus
NRT compared with NRT alone, albeit with widely differ-
ent study populations and smoking phenotypes [5–9]. In
all six trials there is no evidence of benefit (OR = 1.29,
95% CI = 0.63–2.62—author random-effects meta-
analysis). No trials have since tested the combination
against bupropion alone, arguably a more relevant com-
parison given that the evidence points towards bupropion
being more effective than NRT.
With much uncertainty remaining, we conducted an
effectiveness trial of these therapies in a clinical practice
setting. Three main questions were addressed: (i) is there
a difference in effectiveness between NRT and bupropion;
(ii) is the combination superior to either treatment alone;
and (iii) can subgroups be identified who would benefit
more from one or other treatment?
METHODS
Study overview
This was an investigator-led trial conducted in four
National Health Service (NHS) smoking cessation ser-
vices, sited at the Maudsley Hospital, London (n = 216),
the Royal London Hospital (n = 276), the South-East
Essex Stop Smoking Service (n = 321) and the Haringey
and Enfield Stop Smoking Service, London (n = 258).
Local research ethics approval was received for each site.
The UKMedical Research Council oversawmanagement,
with funding provided by the Department of Health for
England. The trial was sponsored by Kings College
London and authorized by the Medicines and Healthcare
products Regulatory Agency (MHRA). All participants
gave informed consent. The first participant enrolled on
15 June 2004 and the database was completed on 30
September 2007.
Study design
This was an open-label parallel-group trial with partici-
pants randomized to NRT or bupropion or NRT plus
bupropion. Given the established efficacy of NRT and
bupropion as single therapies, a group receiving no treat-
ment or a placebo was considered unethical and imprac-
ticable. Because all medicines had been used as equal
first-line treatments for several years in theNHS, an open-
label design was not considered likely to induce a bias in
favour of a particular treatment.
Randomization was in the ratio 7 : 7 : 4 for NRT,
bupropion and the combination, respectively, to reflect
the importance of the main comparison between NRT
and bupropion alone. Behavioural support was provided
in the usual style at each clinic, involving seven weekly,
mainly group support, sessions (each 60–90 min)
over 6 weeks: (i) assessment/screening, (ii) preparation,
(iii) quit-day, (iv) week 1 post-quit, (v) week 2 post-quit,
(vi) week 3 post-quit and (vii) week 4 post-quit [10,11].
Trial participants followed the same procedures and
treatment protocol as usual-care smokers, the only
additions being random assignment to treatments and
follow-up at 6 months.
Following usual clinical practice, smokers contact-
ing each clinic for help were booked to attend the next
treatment course at their convenience. An information
pack was sent out before the first session. This included
a self-completion questionnaire to aid assessment and
a letter explaining the trial and inviting them to
participate. Between 10 and 30 smokers attended each
course, depending on demand at the time. At the first
session individual assessment preceded information
in a group on the treatment options offered. Those
interested in trial participation were screened individu-
ally for eligibility and, depending on the preference of
each clinic, consent and randomization took place
either at this time or at the next (pre-quit) session,
1 week later.
Participants received cessation support in groups that
included smokers who had not enrolled in the trial.
Session 2 (preparation) consisted of therapist guidance
and group discussion in preparation for quit day. Those
taking bupropion started their medication after this
session. Those using NRT started treatment from session
3 (quit day) and all participants were encouraged to stop
smoking completely from that day onwards. Weekly
support was given at sessions 4–7 (1–4 weeks after quit
day). Those failing to attend the final session were con-
tacted and encouraged to attend at a later time. Three
attempts were made to contact all participants 26 weeks
later, and those reporting not having smoked during the
previous 7 days were invited to attend for a brief
follow-up assessment for which travelling expenses were
reimbursed. Blind follow-ups were not considered feasi-
ble, due to patients usually discussing their treatment
when contacted.
Study sample
Participants were daily smokers who did not express a
preference for a particular treatment, were able to under-
stand the trial procedures, were willing to participate,
and for whom neither NRT nor bupropion were
contraindicated according to the summary of product
characteristics (SpC).
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Study medication
Study medication was provided free of charge to the
trial in standard packaging by all the manufacturers
(Pfizer UK, GSK UK, Novartis UK). NRT was dispensed by
trial clinicians/pharmacists under whichever scheme
operated locally. At two sites with prescribing doctors,
bupropion was dispensed under arrangement with the
local pharmacy. At the two sites without doctors,
bupropion was prescribed in the usual way by the partici-
pant’s primary care doctor [general practitioner (GP)],
following screening at the clinic. GPs were asked to
adhere to the randomized treatment assignment.
Following usual practice in NHS clinics, participants
assigned to NRT could choose a single product, after con-
sultation with clinic staff regarding such considerations
as previous experience with products and appropriate
dosage. Dosage over the 12-week course could be
adjusted or the product type changed as considered nec-
essary. Participants assigned to bupropion took 150 mg
bupropion for the first 6 days and 300 mg for the remain-
der of the 8-week course, in line with the SpC. The dose
could be reduced if considered necessary and those expe-
riencing unacceptable symptoms could stop taking
bupropion and switch to NRT. Following NHS practice,
medication was dispensed to participants in batches over
time [12]. It was usually given every 2 weeks throughout
the support phase until the final session (session 7) when
the remainder of the course was dispensed to those
continuing.
Study procedures and measures
To allow participants to be recruited at satellite centres
without computer links, randomization was by sealed
envelope. Numbered envelopes containing a random
treatment allocationwere provided to each site. On enrol-
ment participants selected their envelope from a large
batch and signed it before breaking the seal to reveal their
allocation. Randomization and packaging was organized
by an independent statistician at the host site, using the
SPSS softwareRand function.The sites received batches of
90 envelopes as required throughout recruitment, each
consisting of five blocks of 18 random assignments
(seven NRT, seven bupropion, four NRT + bupropion).
Participants completed the usual clinic materials. The
pre-treatment questionnaire included items relating to
demographics, smoking history, tobacco dependence,
previous attempts to stop andmedical history [13]. It was
self-completed and responses were reviewed with a clini-
cian at the first session. At the start of sessions 2–7, par-
ticipants completed a form detailing smoking behaviour
and use of medications throughout the previous week.
At session 2 this included ratings of mood effects and
from session 3 onwards a section where up to three
unwanted symptoms could be reported. When reported,
the intensity of the symptom was self-rated: 1 = mild,
2 = moderate, 3 = severe. Before each support session
a therapist reviewed the responses and recorded an
expired-air carbonmonoxidemeasure (ECO). At 6-month
follow-up participants completed a questionnaire detail-
ing their smoking behaviour since the last support
session and an ECO was taken.
Outcome measures and data analysis
The primary outcome measure followed the Russell
Standard criterion for 6 months cessation (RS6) [14],
defined as a self-report not having smoked more than five
cigarettes between the end of the second week post-quit
(session 5) and the 6-month follow-up (including com-
plete abstinence during weeks 3 and 4 post-quit and
during the final week of follow-up), and recording an ECO
level of <10 parts per million (p.p.m.) at session 7 and at
6 months. Hence, patients needed to self-report 2 weeks
of abstinence and be validated at session 7 (end of treat-
ment) and to report 6 months of abstinence and be
validated at the 6-month follow-up, with the allowance
of only five cigarettes having been smoked over the
follow-up period. Secondary measures were point-
prevalence at 6 months (PP6), defined as a self-report of
completed abstinence during the final week of follow-up
and an ECO level <10 p.p.m., and the Department of
Health short-termmonitoring measure (DH4), defined as
a self-report of complete abstinence duringweeks 3 and 4
post-quit and an ECO level <10 p.p.m. at session 7. By
definition, all those classified as RS6 abstinent were also
DH4 and PP6 abstinent. Those not attending session 7 or
at 6monthswere considered as continuing smokers, or to
have relapsed [14,15].
The studywas designed to detect as significant an odds
ratio of 1.5 for bupropion versus NRTwhich, based on an
anticipated 25% 6-month cessation rate with NRT (34%
bupropion) and with alpha and beta (1-power) set at
0.05, would require sample sizes of 700 (NRT) and 700
(bupropion). Given the weaker prior evidence for the
combination compared with bupropion, 0.90 power was
considered appropriate for this comparison (i.e. 44 versus
34%), requiring an additional 400 participants in a com-
bination group (1800 participants in total). In the event,
recruitment was slower than anticipated over the time
clinics allocated and the trial closed with 1071 partici-
pants (418 NRT, 409 bupropion, 244 combination). It
remained considerably larger than themanufacturer trial
[1], and had 0.90 power to detect an odds ratio of 1.6 for
bupropion versus NRT (i.e. 35% versus 25%).
Data were entered initially into local databases before
transfer to a database at the lead site. Smoking cessation
rates were compared using the OR with 95% CI, and
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logistic regression models were used to adjust for
potentially confounding antecedent characteristics. We
examined whether there were subgroups who benefited
particularly from either NRT or bupropion by fitting
logistic regression models with interaction terms for
treatment by each of the characteristics of interest. The
trial protocol specified that if there was no difference
between single treatments, pooled data would be used
for comparison with combination treatment. Unwanted
symptom incidence and intensity were compared using
χ2 tests. Data were processed and examined only after
all follow-ups had been completed and the data file
closed.
RESULTS
Characteristics of the participants
Table 1 shows the participant characteristics by treat-
ment arm. Overall, 47%weremale and themean agewas
41 years. They smoked an average 20 cigarettes per day
(range three to 60). About 40% reported a history of a
major illness associated with smoking and more than a
quarter reported a history of depression. Approximately
60 and 6%, respectively, had used NRT and bupropion
previously, and 38% had succeeded in stopping smoking
for as long as 1 month in the previous 5 years. In those
assigned to NRT, 48% (201 of 418) chose to use the
patch, with approximately equal numbers using the
other five product types (gums, lozenges, inhalator, nasal
spray and microtab).
Figure 1 shows the flow of participants through the
trial [16]. Those not enrolled were divided approxi-
mately equally between those having a treatment
preference and therefore being unwilling to be rando-
mized (n = 2503) and those for whom bupropion was
contraindicated (n = 2595). In the two sites where local
GPs were required to prescribe bupropion, 57 partici-
pants were refused prescriptions. The reported reasons
appeared to be mainly unrelated to contraindications or
cautions and were due either to the GP misunderstand-
ing these or possibly having an individual prejudice
against bupropion. In 27 of these cases the participant
either switched to NRT (21 of 36) or continued NRT
alone (six of 21). The remaining 20 participants pre-
ferred to continue without medication. The two follow-
ups for the primary outcome (session 7, 26 weeks) were
completed by 659 (61.5%) participants and this rate
did not differ significantly between treatment groups
(χ2(2) = 3.33, P = 0.19). Of the 412 participants not
completing both follow-ups, 241 (58.5%) reported
smoking at one follow-up which they did complete,
meaning that they could not be classified as RS6
abstinent. Hence, only for the remaining 171 (16.0% of
all participants) who either did not respond to either
follow-up or who were abstinent at one follow-up, but
did not respond to the other, was it was necessary
to assume continued smoking. This gave a primary
Table 1 Characteristics of participants on entry to the trial.
NRT
(n = 418)
Bupropion
(n = 409)
NRT and bupropion
(n = 244)
Demographics
% Male (n) 47.8 (200) 45.5 (186) 47.0 (115)
Age, mean (SD) 40.8 (11.9) 40.7 (11.7) 41.2 (12.1)
% White European origin (n) 78.2 (327) 78.5 (321) 79.5 (194)
% No school or college qualifications (n) 23.2 (97) 26.4 (108) 20.1 (49)
% Receiving state benefits (n) 33.3 (139) 37.2 (152) 38.1 (93)
Health
% Life-time history of major illness related to smoking (n) 37.1 (155) 40.1 (164) 42.6 (104)
% Life-time history of depression (n) 25.8 (108) 25.7 (105) 27.0 (66)
% Life-time history of drug or alcohol problems (n) 4.55 (19) 3.91 (16) 4.51 (11)
Tobacco smoking
Usual daily cigarettes smoked, mean (SD) 20.7 (8.7) 19.8 (8.1) 20.3 (9.7)
HSI score, mean (SD)a 3.26 (1.41) 3.13 (1.48) 3.28 (1.47)
% ‘Very’ or ‘totally’ determined to stop at this attempt (n) 77.3 (323) 77.8 (318) 71.7 (175)
Confidence in stopping at this attempt (1–10), mean (SD)b 7.49 (2.02) 7.59 (1.93) 7.29 (1.97)
% Stopped for more than 1 month in last 5 years (n) 37.1 (155) 38.1 (156) 38.5 (94)
% Previously failed with NRT (n) 59.1 (247) 61.1 (250) 61.5 (150)
% Previously failed with bupropion (n) 7.42 (31) 4.16 (17) 8.20 (20)
aHeaviness of Smoking Index (HIS) scored as 0 (light)—6 (heavy), four subjects not recorded; b69 participants not recorded. There was no detectable
evidence of chance imbalances in the distributions of any of the characteristics shown when these were compared between the three cohorts (all
P > 0.05). NRT = nicotine replacement therapy; SD = standard deviation.
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outcome completion rate of 84%. Again, this rate did
not differ between treatment groups.
Outcomes
Abstinence rates were compared in the full sample as
randomized (intention-to-treat—ITT sample) and in the
sample excluding the 57 participants known not to have
received their assigned treatment (treated sample). There
was no evidence of an effectiveness difference between
bupropion and NRT on any primary or secondary
outcome measure in either the ITT or treated samples
(Table 2). Although the OR appeared to increase in
favour of bupropion between the short-term (DH4) and
RS6 outcomes, relapse rates between these times were
not significantly different (58.9%NRT, 50.5% bupropion;
difference = 8.5%, 95% CI = −0.5 to 17.9%). There
was also no evidence that compared with either single
Screened for inclusion (n=6220)  
Total excluded or declined (n= 5149) 
Excluded - bupropion contraindication 
(n=2595) 
Excluded - not competent to understand trial 
(n=51) 
Declined - unwilling to be randomised 
(n=2503) 
Analysed (n=418) Excluded (n=0)*                     
* ITT analysis with those failing to respond 
assumed to have continued smoking 
Not completing all follow-ups necessary for 
primary outcome (n=148) 
Known lack of efficacy (n=76) 
Assumed lack of efficacy (n=72)* 
Allocated to NRT (n=418) 
Received allocated intervention (n=418)
Did not receive allocated intervention (n=0)
Not completing all follow-ups necessary for 
primary outcome (n=170) 
Known lack of efficacy (n=109) 
Assumed lack of efficacy (n=61)* 
Allocated to bupropion (n=409) 
Received allocated intervention (n=373)
Did not receive allocated intervention (n=36)
Analysed (n=409) Excluded (n=0)*
* ITT analysis with those failing to respond 
assumed to have continued smoking
Allocation
Analysis
Follow-Up
Randomized (n=1071) 
Enrollment
Allocated to combination (n=244) 
Received allocated intervention (n=223)
Did not receive allocated intervention (n=21)
Not completing all follow-ups necessary for 
primary outcome (n=94) 
Known lack of efficacy (n=56) 
Assumed lack of efficacy (n=38)* 
Analysed (n=244) Excluded (n=0)*
* ITT analysis with those failing to respond 
assumed to have continued smoking
Figure 1 Flow of participants through the trial
Table 2 Smoking cessation outcome.
Outcome measure NRT Bupropion Combination
Odds ratio bupropion
versus NRT (95% CI)
Odds ratio combination
versus pooled NRT and
bupropion (95% CI)
ITT samplea (n = 418) (n = 409) (n = 244)
Primary outcome (RS6) % (n) 24.2 (101) 26.7 (109) 23.4 (57) 1.14 (0.834–1.56) 0.896 (0.640–1.25)
Secondary outcome (DH4) % (n) 58.9 (246) 53.8 (220) 54.5 (133) 0.814 (0.618–1.07) 0.928 (0.697–1.24)
Secondary outcome (PP6) % (n) 28.2 (118) 32.3 (132) 27.5 (67) 1.21 (0.900–1.63) 0.874 (0.636–1.20)
Treated sampleb (n = 418) (n = 373) (n = 223)
Primary outcome (RS6) % (n) 24.2 (101) 27.9 (104) 24.2 (54) 1.21 (0.883–1.67) 0.913 (0.647–1.29)
Secondary outcome (DH4) % (n) 58.9 (246) 54.4 (203) 55.6 (124) 0.835 (0.63–1.11) 0.954 (0.707–1.29)
Secondary outcome (PP6) % (n) 28.2 (118) 33.8 (126) 28.7 (64) 1.30 (0.959–1.76) 0.902 (0.651–1.25)
RS6 = Russell Standard sustained 6-month carbon monoxide (CO)-verified cessation; DH4 = Department of Health weeks 3 and 4 post-quit day
CO-verified cessation; PP6 = 7-day CO-verified point prevalence at 6 months. aIntention-to-treat (ITT)—sample as randomized. bTreated sample—
excluding 57 participants known not to have received bupropion. CI = confidence interval; NRT = nicotine replacement therapy.
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treatment, or the two single-treatment groups pooled
together, that combination treatment was more effective.
Although there was evidence that RS6 abstinence
rates differed between the four study sites (χ2(3) = 13.7,
P = 0.003), there was no evidence of a differential treat-
ment effect (heterogeneity) across sites (χ2(3) = 1.24,
P = 0.745), or between the two sites who dispensed
bupropion directly and the two sites which relied upon
local GPs for bupropion prescriptions (χ2(1) = 0.372,
P = 0.542). Effect sizes were only marginally altered in
logistic regression models that adjusted for all the base-
line characteristics shown in Table 1. Among those
assigned to NRT, RS6 success rates were similar between
the six product types (χ2(5) = 6.6, P = 0.247), with
26.9% of patch users (versus 26.7% bupropion) being
successful.
Subgroup analyses
To examine if the effect of treatment was moderated for
subgroups we fitted logistic regression models with inter-
action terms for treatment by each of the characteristics
shown in Table 1. For this analysis we included only the
1014 participants known to have received their assigned
treatment. Among these characteristics, only for life-
time history of depression was there some evidence of a
differential treatment effect (χ2 = 6.5, P = 0.011 and
χ2 = 2.86, P = 0.091 for DH4 and RS6, respectively). This
can be interpreted as there being evidence that bupropion
was more effective than NRT for those with a history
of depression (RS6: 29.8 versus 18.5%, χ2 = 3.523,
P = 0.061) and there being no difference between treat-
ments for those without a history of depression (Fig. 2).
Alternatively, for those using NRT, a depression history
was detrimental to success (DH4: P = 0.03; RS6: P =
0.075), whereas for those taking bupropion this effect
was ameliorated (DH4: P = 0.246; RS6: P = 0.630). In all
subjects, if treatment and interaction parameters are
ignored, a history of depression did not affect the likeli-
hood of success (DH4: P = 0.443; RS6: P = 0.418).
Unwanted symptoms and use of medication
There were three cases of allergic reaction to bupropion,
two of which resulted in anaphylaxis and required
hospital admission. A fourth participant reported tearful-
ness and transient suicidal thoughts. These cases, plus
one case of severe chest pain, were withdrawn from
bupropion and offered NRT to continue their quit
attempt. There were no such serious adverse events in the
NRT group. Table 3 shows the incidence of non-serious
unwanted symptoms as described by participants on the
weekly forms after the commencement of treatment at
sessions 3–7. Disturbed sleep was the most common
symptom and experienced by more than 30% of those
taking bupropion. Incidences of dry mouth, headache,
nausea, dizziness, low mood/depression, anxiety/panic,
chest pain, disorientation and loss of appetite were also
higher among those taking bupropion. Nasal irritation
(nicotine nasal spray) and skin irritation (nicotine patch)
were more common among those using NRT. Among
those experiencing symptoms, ratings of intensity were
not significantly different between treatments. At session
2, before medication was started, there were no differ-
ences (all P > 0.05, data not shown) between the treat-
ment conditions in the incidence of any of the mood
effects similar to those reported later as unwanted
symptoms (depression, irritability, restlessness, disturbed
sleep, appetite).
Use of medication was assessed among those absti-
nent (DH4) at 4 weeks (session 7). Seventy-six per cent
(187 of 246) of those assigned NRT, compared with
63.1% (128 of 203) of those assigned bupropion, were
continuing to use their medication on 5 or more days per
week (χ2 = 8.9, P = 0.003). Of those assigned bupropion,
20.2% (41 of 203) had disliked the symptoms they attrib-
uted to it sufficiently to switch to NRT. Similarly, among
those assigned combination treatment, 71 and 61%were
using NRT and bupropion, respectively, on 5 ormore days
per week at this time.
DISCUSSION
We did not find evidence of an effectiveness difference
between NRT, bupropion and their combination. With
particular reference to the original manufacturer trial
[1], we found no evidence of a difference between the
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Figure 2 Relation between treatment, history of depression and
smoking cessation at 4 and 26 weeks after quit day. NRT = nicotine
replacement therapy
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nicotine patch and bupropion, although this comparison
was not planned and involved self-selection of the nico-
tine patch in preference to other NRT products. Conse-
quently, our results did not generalize to clinical practice
the original efficacy findings of that trial with regard to
the main comparison between bupropion and NRT, and
were instead consistent with two other smaller efficacy
trials [2,3]. The only clear similarity in findings between
ours and the original trial was that both reported a higher
incidence of unwanted symptoms among those taking
bupropion.
Given the divergence of findings comparing NRT and
bupropion, evidence from the indirect comparison of
numerous trials separately assessing NRT and bupropion
should be considered. From 132 trials comparing any
type of NRT with placebo or no treatment, the relative
rate is 1.58 (95% CI = 1.50–1.66) [17]. From 36
bupropion trials the equivalent rate is 1.69 (95%
CI = 1.53–1.85) [4]. The ratio of these two rates (1.69/
1.58 = 1.07) is extremely close to that observed in the
current trial (i.e. 26.7/24.2% = 1.10) and not distin-
guishable from1.Therefore, the indirect comparison sup-
ports our finding rather than those of the original trial
and its higher rate of 2.07 (1.2–3.5).
The reason why the manufacturer trial gave results
at odds with subsequent findings cannot be discerned
clearly. Regarding the comparison with our trial, an
important design difference was our allowance for par-
ticipants to select between all NRT products, rather than
using only the nicotine patch. Although this feature
models clinical practice more closely and the need for
clinics to encourage smokers into treatment by being
responsive to their preferences, it is unlikely to have
boosted the NRT success rate sufficiently to have
accounted for the difference. To date, there is no clear
evidence of a difference in effectiveness between different
NRT products or that individuals can select optimal prod-
ucts [17]. It is possible that the strict inclusion/exclusion
criteria in the manufacturer trial played a part, and that
the far less restrictive criteria currently recommended for
clinical practice allowed too many to use bupropion for
whom it was unsuitable. This is possibly supported by our
significantly poorer level of compliance with bupropion
than NRT among those abstinent at 4 weeks. Although
no specific data on compliance were given in Jorenby
et al., the dropout rates published probably suggest
similar levels of compliance in that trial.
Our trial had many of the limitations inherent in
effectiveness trials conducted in routine clinical practice.
Principally, we could not include placebos to allow a
no-treatment condition or to blind treatment allocation
and, although we waited until all treatments had long
become routine before conducting the trial, preference
bias remains a possibility. We were also unable to assess
medication compliance comprehensively due to patients
failing to attend or respond to enquiries. Additionally,
we were unable to achieve the designed sample size,
although lack of statistical power is unlikely to have been
Table 3 Unwanted symptoms after the commencement of treatment.a
Symptom
NRT (n = 418) Bupropion (n = 409)
NRT plus bupropion
(n = 244)
Incidence n (%)b Incidence n (%)b Incidence n (%)b
Disturbed sleep 53 (12.7) 125 (30.6)c 76 (31.1)d
Vivid dreams 30 (7.2) 22 (5.4) 12 (4.9)
Skin irritation 30 (7.2)c,d 11 (2.7) 8 (3.3)
Sore throat/mouth 29 (6.9) 31 (7.6) 22 (9.0)
Headache 18 (4.3) 44 (10.8)c 21 (8.6)d
Bad taste 16 (3.8) 26 (6.4) 13 (5.3)
Irritation/agitation 16 (3.8) 17 (4.2) 18 (7.4)
Constipation 15 (3.6) 24 (5.9) 14 (5.7)
Nasal irritation 13 (3.1)c 3 (0.7) 3 (1.2)
Dry mouth 10 (2.4) 52 (12.7)c 30 (12.3)d
Nausea 9 (2.2) 24 (5.9)c 21 (8.6)d
Dizziness/lightheaded 5 (1.2) 22 (5.4)c 14 (5.7)d
Low mood/depression 2 (0.5) 17 (4.2)c 8 (3.3)
Chest pain 2 (0.5) 9 (2.2)c 5 (2.0)
Disorientated/confusion 2 (0.5) 7 (1.7) 7 (2.9)d
Loss of appetite 1 (0.2) 7 (1.7)c 6 (2.5)d
Anxiety/panic 1 (0.2) 12 (2.9)c 5 (2.0)
aSymptoms reported significantly more in comparisons or by at least 5% of participants in any treatment group, ordered by incidence in nicotine
replacement therapy (NRT) cohort. bSelf-rated as moderate or severe in intensity at any time throughout treatment. cTreatment with higher incidence,
bupropion versus NRT (χ2, P < 0.05). dTreatment with higher incidence, combination versus NRT (χ2, P < 0.05).
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a serious limitation. If our estimated bupropion versus
NRT difference approximates the true difference, as sup-
ported by an indirect comparison, a sample size of
approximately 10 000 would be required to detect this as
statistically significant. More importantly, it would prob-
ably be of negligible clinical significance.
With these findings in mind, it is worth considering
the position of bupropion for smoking cessation.
Bupropion efficacy appears to be lower than for
varenicline [18], and while apparently similarly as effec-
tive as NRT, it causes a higher incidence of some
unwanted effects (nine effects noted in this study as
against two effects with higher NRT incidence). Might
unwanted events be reduced without loss of efficacy
with 150 rather than 300 mg bupropion? The original
dose-ranging trial would suggest so [19]. Longer-term
cessation rates for 150- and 300-mg doses were indistin-
guishable, while there were more withdrawals and
serious unwanted events with 300 mg. Without further
research into the potential of optimal dosing, current
evidence suggests bupropion might be second line for
those failing with NRT or varenicline, although its cost-
per-week benefit over these treatments is an advantage.
A potentially unique benefit for bupropion over NRT
was our observation of a possible improvement in absti-
nence for those reporting a history of depression. This
might be tested in future in a randomized controlled trial
among those with a history of depression. Bupropion
ameliorated the somewhat detrimental effect of depres-
sion observed with NRT, with a suggestion that when
given bupropion those with depression, compared with
those without, were more successful. Although this
seems plausible, given bupropion’s previous indication
as an antidepressant, in three previous studies that
compared bupropion with either placebo or low-dose
bupropion no such additional benefit was observed
among those with a history of depression [20–22]. Taken
together, these results would suggest that if bupropion is
not additionally beneficial for those with a depression
history, then NRT might at best be ineffectual, or even
detrimental, for such smokers. Researchers with older
data sets where depression history was recorded might
investigate this. Perhaps surprisingly, our analysis of
depression does not appear to have been undertaken in
the three previous trials comparing bupropion with NRT
[1–3]. Given the high prevalence of depression among
smokers seeking help to stop, our tentative finding merits
further study [23].
Clinical trial registration
International Standard Randomised Controlled Trial
Number: ISRCTN91464711.
http://www.controlled-trials.com/ISRCTN91464711
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